Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

Summary

Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.

Timeline

Start

2011-04

Primary completion

2012-10

Completion

2013-04

Outcome

Missed primary endpoint

registry Continued Tenofovir/Emtricitabine/Efavirenz vs Switch to Tenofovir/Emtricitabine Plus Raltegravir; p = 0.67; Mean Difference (Net) 0.81 (95% CI -0.75 to 2.37) NCT01270802 ↗

Drugs

Indications